Skip to main content
Premium Trial:

Request an Annual Quote

Protein Dx Firm Courtagen Raises $8M

NEW YORK (GenomeWeb News) – Courtagen Life Sciences has raised $8 million in equity funding, the company disclosed in a regulatory filing on Friday.

The document filed with the US Securities Exchange Commission did not reveal how the funds will be used or who the participants in the round were but said that there were 67 investors.

A company spokesperson did not respond to a request for comment.

The new funding follows $7 million raised by the Woburn, Mass.-based protein diagnostics firm last year. Courtagen was launched in late 2009 from the assets of the now-defunct Decision Biomarkers when the Courtagen Capital Group purchased them and formed a company called Avantra Biosciences. Last month, Avantra changed its name to Courtagen.

In January Courtagen launched its Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay for quantifying cancer protein biomarkers.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.